Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.

ABSTRACT:

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potential curative therapy for myelodysplastic syndrome (MDS), recommended in higher risk disease according to the International Prognostic Scoring System (IPSS). We conducted a phase 2 multicenter trial (MDS-ALLO-RISK) investigating whether allogeneic HSCT improves overall survival (OS) in patients with lower-risk MDS who exhibit additional high-risk features (intermediate or higher revised-IPSS risk, thrombocytopenia with <20 × 109/L, neutropenia <0.5 × 109/L, or failure to 2 lines of therapy). A total of 77 patients (median age, 62.5 years) with low or intermediate-1 IPSS scores were enrolled and stratified based on the presence of a matched HLA donor, 62 patients in the donor arm and 15 without

SUBMITTER: Sebert M 

PROVIDER: S-EPMC12856338 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature